Dr. Jamie Chaft says neoadjuvant chemoimmunotherapy offers thoracic oncologists an opportunity to cure more patients. Read more
Dr. Mary O’Brien and colleagues say decision making around operable cases is becoming increasingly complex, making a multidisciplinary approach imperative. Read more
In Part 2 of their exploration of artificial intelligence, Dr. Raymond Mak and Fridolin Haugg reflect on the possibilities ahead for the diagnosis and treatment of lung cancer. Read more
Dr. Barbara Andersen’s research has shown depression severity is associated with prognostically poor inflammation in patients with non-small cell lung cancer. Read more
IASLC Hot Topic meeting to feature keynote address on resistance to immunotherapy by Dr. Drew Pardoll. Lung Cancer Research Foundation announces appointment of new executive director Aubrey Rhodes. Read more
Dr. Raymond Mak and Fridolin Haugg delve into the artificial intelligence discussion with an overview of AI basics and a look at how AI is already influencing the lung cancer field. Read more
When life-and-death decisions are at stake, will patients welcome AI to their care team? As part of ILCN’s series on AI in lung cancer, patient advocate Angus Pratt explores issues of trust, safety, accuracy, and more. Read more
Dr. Quincy Chu recently shared results from the phase III IND227 trial, which also demonstrated improved progression-free survival in mesothelioma patients who received the combination compared to those who received standard chemotherapy alone. Read more
In stage II-IIIA NSCLC patients with high PD-L1 expression, the benefits of atezolizumab and platinum-based chemotherapy after surgical resection appeared to be most prominent in the lobectomy subgroup according to Dr. Alessandro Brunelli and colleagues. Read more
Editor-in-Chief Dr. Alex Adjei announced the journal’s impact factor once again rose in 2022 and says it remains the leading journal in thoracic oncology. Read more